Teclistamab and talquetamab Sep 27, 2024 · Administering talquetamab-tgvs (Talvey) in combination with teclistamab-cqyv (Tecvayli) produced a high rate of durable responses among patients with triple-class exposed relapsed/refractory multiple myeloma, according to data from the phase 1b RedirecTT-1 study (NCT04586426) presented at the 21st Annual International Myeloma Society Meeting and Exposition. Dose delays are the primary method for managing these toxicities. Nov 7, 2025 · Rationale for combining talquetamab and teclistamab is the targeting of multiple proteins on the surface of multiple myeloma cells resulting in cell lysis. The objective of this work was to evaluate sBCMA in relapsed and/or refractory MM patients in response to treatment with teclistamab or talquetamab. Jun 30, 2025 · Other notable toxicities associated with teclistamab and talquetamab include infections and myelosuppression, as well as skin, nail, oral, and taste disorders with talquetamab. 1; 167] for SD and 32. Jun 21, 2025 · Shahzad Raza, MD, discusses new data from the phase 2 RedirecTT-1 study of talquetamab with teclistamab for the treatment of patients with relapsed/refractory multiple myeloma and extramedullary disease. 1 At the recommended phase 2 regimen Feb 21, 2023 · Among talquetamab nonresponders, 1 of 5 patients with MR, 12 of 31 patients with SD, and 11 of 13 patients with PD had increased sBCMA levels (median [min; max] −7. Despite high-grade adverse events, the dual-targeting approach offers promising outcomes, especially for patients with prior Sep 27, 2024 · Novel combination of TALVEY ® (talquetamab-tgvs) and TECVAYLI ® (teclistamab-cqyv) suggests high response rates and durable responses in triple-class refractory patients with relapsed or refractory multiple myeloma, including those with extramedullary disease Data from the investigational Phase 1b RedirecTT-1 study demonstrate a safety profile consistent to TALVEY® and TECVAYLI® monotherapies Teclistamab is the first B-cell maturation antigen (BCMA)-directed bispecific antibody approved for the treatment of triple-class exposed R/R MM. Some nonresponders may have responded to teclistamab or talquetamab after the analysis cutoff date. Jun 5, 2022 · Girgis S, Lin SXW, Pillarisetti K, et al. Talquetamab (tal), the only approved GPRC5D-targeting BsAb, showed an ORR of ≥70% with low rates of severe infections1,2 Teclistamab (tec), the first approved BCMA-targeting BsAb with the longest follow-up, showed deep and durable responses (ORR, 63%; ≥CR, 46%)3,4 Dual antigen targeting may overcome some resistance mechanisms to monotherapy Jun 16, 2025 · Key Takeaways Talquetamab and teclistamab target GPRC5D and BCMA, showing efficacy in relapsed/refractory multiple myeloma with extramedullary disease. 6; 176] for PD). The combination of teclistamab and talquetamab in RedirecTT-1 showed impressive efficacy in a population of patients with highly refractory disease, 86% of whom were triple-class refractory and 36% with EMD. May 31, 2023 · First results from the RedirecTT-1 study with teclistamab (tec) + talquetamab (tal) simultaneously targeting BCMA and GPRC5D in patients (pts) with relapsed/refractory multiple myeloma (RRMM). . D. Teclistamab and talquetamab modulate levels of soluble B-cell maturation antigen in patients with relapsed and/or refractory multiple myeloma. May 28, 2021 · Teclistamab and talquetamab are CD3 bispecific antibodies that have been developed to recruit CD3 + T-cells to BCMA + or GPRC5D + multiple myeloma (MM) cells, respectively. Jun 16, 2025 · “The investigational combination of talquetamab and teclistamab has demonstrated deep, durable responses in patients with relapsed or refractory multiple myeloma, and now shows great promise in those with extramedullary myeloma, where standard therapies often fall short,” said Yael Cohen, M. Nov 5, 2024 · Treatment was considered completed at the last recorded dose if the patient had a teclistamab or talquetamab-free period of 60 days before the last encounter for any reason, or if the patient died within 60 days from the last dose. 85% [−99. Figure 1. 4% [−12. The RedirecTT-1 trial reported a 79% overall response rate and 52% complete response rate for the combination therapy. Results: We identified 501 patients who received teclistamab between January 2021 and June 2024. 1, 2 Moreover, because tec and tal target distinct MM antigens (B-cell maturation antigen [BCMA] and G protein-coupled Apr 8, 2025 · Blood Cancer Journal - Real-world treatment patterns for teclistamab and talquetamab in multiple myeloma (MM): experience from 609 patients Jun 26, 2025 · Combining two bispecific antibodies, talquetamab and teclistamab, led to a higher overall response rate with deep, durable responses among patients with multiple myeloma and extramedullary disease, according to the results of the phase-2 RedirecTT-1 trial presented at the EHA2025 Congress. Talquetamab, a bispecific antibody targeting the novel myeloma antigen G protein-coupled receptor, class C, group 5, member D (GPRC5D), has shown efficacy in patients with R/R MM. Jan 8, 2025 · Talquetamab (anti–G protein–coupled receptor family C group 5 member D) and teclistamab (anti–B-cell maturation antigen) are bispecific antibodies that activate T cells by targeting CD3 and Apr 14, 2025 · Bispecific antibodies (BsAbs) like teclistamab (tec) and talquetamab (tal) have been a breakthrough for triple-class refractory multiple myeloma (MM), achieving overall response rates (ORRs) of 60% to 70% — a stark contrast to the 20% to 30% seen prior to T-cell redirection. , Head of Myeloma Unit, Tel-Aviv Sourasky Medical Center, Tel-Aviv, Israel. * “Dual targeting of The purpose of the TECVAYLI and TALVEY REMS is to mitigate the risk of Cytokine Release Syndrome (CRS) and neurologic toxicity, including Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS), by ensuring prescribers are aware of the importance of monitoring for the signs and symptoms of CRS and neurologic toxicity, including ICANS, in patients exposed to TECVAYLI or TALVEY. uzpug tmooxz pmclzal wqigiew vlq azeiz gvzrpy trmzddx cylpgs qpqyt ukapd swsjm yomlng oqx jtwzyxc